

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Off : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi -110058
Dated 04.08.2017 CIN : U85191DL2011PLC216530

The Secretary
National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (E),
Mumbai - 400051

The Secretary
Bombay Stock Exchange Ltd
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Sub: Outcome of the Board Meeting held on 04th August, 2017

Dear Sir/ Madam,

We wish to inform you that Board of Directors of the Company in their meeting held on 04.08.2017 has inter alia approved the following:

1. On recommendation of the Audit Committee the Board of Directors has approved un-audited financial results for the quarter ended 30th June, 2017.

Also, Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we enclose the following:

- a. Statement showing the un-audited financial results for the quarter ended 30th June, 2017.
 - b. Limited Review report with respect to the un-audited financial results for the quarter ended 30th June, 2017.
2. The Annual General Meeting of Company will be held on 28th September, 2017 at New Delhi.
 3. Further pursuant to Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has appointed Mrs. Devlina Chakravarty as a Managing Director (Women Director) w.e.f 04.08.2017 and Mr. Ugar Sain Anand as a Independent Director w.e.f 04.08.2017

The Board Meeting commenced at 12.30 p.m. and concluded at 1.10 Pm.

Please take the above information on your records.

Thanking you

Yours Faithfully

For Artemis Global Life Sciences Ltd.

Anuj Sood

Anuj Sood
Company Secretary (A35276)
D-8/10, 3rd Floor Rana Pratap Bagh,
Delhi-110007

Corporate off : SF-202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon - 122002

Website : www.aglsl.in • E-mail: investor@aglsl.in • Tel. 0124 - 4262305/07 • Fax 0124 - 4262306

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No-11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Ph: 47021279

Limited Review Report

To,
The Board of Directors,
Artemis Global Life Sciences Limited


We have reviewed the accompanying statement of unaudited financial results of **Artemis Global Life Sciences Limited** for the quarter ended on 30th June, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 04.08.2017

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N


(Anand Dua)
Partner
M.No. 083503

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Off: 414/1 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi -110058
CIN : U85191DL2011PLC216530

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

PART I		RS. LACS			
SL.NO.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		(UNAUDITED)	Refer Note 3	Refer Note 3	(AUDITED)
I	Revenue from Operations*	10.20	10.20	10.20	40.80
II	Other Income	19.23	-	-	-
III	Total Income from Operations (I+II)	29.43	10.20	10.20	40.80
IV	Expenses				
	(a) Employee benefits expense	3.73	-	-	-
	(b) Legal & Professional Charges	0.58	0.12	0.29	0.49
	(c) Finance Cost	-	-	-	-
	(d) Depreciation and Amortisation Expense	3.41	3.68	3.68	14.71
	(e) Other Expenses	9.41	3.58	0.31	4.48
	Total Expenses (IV)	17.13	7.38	4.28	19.68
V	Profit / (Loss) from Operations before Exceptional Items and Tax (I-IV)	12.30	2.82	5.92	21.12
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) from Ordinary Activities before Tax (V-VI)	12.30	2.82	5.92	21.12
VIII	Tax Expense	3.33	1.58	1.58	6.31
IX	Net Profit/(Loss) from Ordinary Activities after Tax (VII-VIII)	8.97	1.25	4.34	14.81
X	Extraordinary Items (Net of Tax expenses)	-	-	-	-
XI	Net Profit/(Loss) for the Period (IX-X)	8.97	1.25	4.34	14.81
XII	Other comprehensive income (net of tax)				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XIII	Total Comprehensive income	8.97	1.25	4.34	14.81
XII	Paid-up Equity Share Capital (Equity Shares of Rs.2/-each)	1,323.77	1,323.77	1,323.77	1,323.77
XIII	Reserves excluding Revaluation Reserves	**	**	**	14,568.78
XIV	EARNINGS PER SHARE (EPS)				
	Basic EPS before & after Extraordinary Items (Not Annualized) -Rs	0.01	0.00	0.01	0.02
	Diluted EPS before & after Extraordinary Items (Not Annualized) -Rs	0.01	0.00	0.01	0.02

* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

** Not required to be shown

OL

Corporate off : SF-202, Peach Tree, C-Block, Sushant Lok-1, Gurgaon - 122002

Website : www.aglsl.in • E-mail: investor@aglsl.in • Tel: 0124 - 4262305/07 • Fax 0124 - 4262306

NOTES:

- 1 The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
- 2 The scheme of arrangement under sections 391 to 394 of the Companies Act, 1956 read with section 230 to 232 Companies Act, 2013 (the Scheme) between Artemis Global Life Sciences Limited (the Company) and PTL Enterprises Limited (the Demerged Company) and their respective shareholders and the creditors of the two companies for demerger of Medicare and Healthcare Services Business undertaking as a going concern into the Company with the Appointed Date at the opening of business hours on 01st April 2016, has been sanctioned by the Hon'ble High Court of Judicature at Kerala vide its Order dated 16th December, 2016, and the Hon'ble National Company Law Tribunal, New Delhi vide its Order dated 1st March, 2017. Certified copies of the order of the Hon'ble High Court of Judicature at Kerala and Hon'ble National Company Law Tribunal, New Delhi have been filed with the Registrar of Companies at Kerala and Delhi respectively and the scheme has become effective from 8th March 2017.
Hence, 5,00,000 Equity Shares of Rs 2 (Indian Rupees Two Only) each fully paid up of the Company were Cancelled, and 6,61,88,500 equity shares of Rs. 2 (Indian Rupees Two Only) each were allotted to the shareholder of the Demerged Company on March 30, 2017 in the ratio of 1 (One) equity share in Company for every 1 (One) equity shares of Rs. 2/- (Indian Rupees Two Only) each held in the Demerged Company. Accordingly the paidup capital of the Company is Rs. 1323.77 Lacs.
- 3 The results incorporate the impact of the above mentioned demerger from the appointed date April 1, 2016. The results for the quarter ended June 30, 2016 and March 31, 2017 have also been restated accordingly to incorporate the impact of demerger.
- 4 The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and other recognised accounting practices and the policies to the extent applicable. Being April 1, 2017 company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- 5 The Ind AS compliant corresponding figures for the quarter ended Jun 30, 2017, June 30, 2016 and for the year ended March 31, 2017 have not been subjected to review. However the Company management has exercised necessary due diligence to ensure that such financials results provide a true and fair view of its affairs.
- 6 Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to Total Comprehensive Income in accordance with Ind AS is given

S.No.	P A R T I C U L A R S	QUARTER ENDED			RS. LACS
		30.06.2017	31.03.2017	30.06.2016	
		(Refer Note 2)	(Refer Note 2)	(Refer Note 2)	
	Profit for the period as per I GAAP	8.97	1.25	4.34	
	Profit for the period under Ind AS	8.97	1.25	4.34	
	Other Comprehensive income as per Ind AS	-	-	-	
	Total Comprehensive income as per Ind AS	8.97	1.25	4.34	

- 7 Reconciliation of equity as per Previous Indian GAAP (I GAAP) and as per Ind AS is given below

RS. LACS

S.No.	P A R T I C U L A R S	As At	As At
		31.03.2017	01.04.2016
		(Refer Note 2)	(Refer Note 2)
	Equity as per I GAAP	15,883.58	15,868.77
	Equity as per Ind AS	15,883.58	15,868.77

- 8 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 4, 2017. The stand-alone results of the Company have undergone limited review by the Statutory Auditors.

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

Onkar Kanwar

ONKAR S KANWAR
CHAIRMAN

PLACE: GURUGRAM
DATE: AUGUST 4, 2017